|Articles|June 10, 2020
HIV and COVID-19: Pharmacists and Healthcare Systems Mitigate Risks
Author(s)Lindsey Carr, Editor
Approximately 1.1 million people in the U.S. are living with HIV today. In the midst of the global COVID-19 pandemic, a lack of information exists about whether HIV patients are at an increased risk for contracting the virus.
Advertisement
“So far, there is no major report to suggest that HIV patients are more or less susceptible to COVID-19 than individuals who do not have HIV or are otherwise healthy,” Rodney Ho, PhD, professor of pharmaceutics at the University of Washington School of Pharmacy in Seattle, told Drug Topics®. “We don’t know why.”
A new article on Drug Topics® discusses ways in which pharmacists and health care systems are adjusting to mitigate risk.
Read the
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
GLP-1 RAs linked to broad menstrual adverse event signals in reproductive-aged patients
2
A discussion of STI rates, barriers, and home screenings with Damian Alagia III, MD
3
Q+A: Connor Frey, MD, on GLP-1 RAs and menstrual adverse event signals
4
Statewide bundle reduces risk for deliveries complicated by postpartum hemorrhage
5